BioSpace News Archive

Ad hoc announcement pursuant to Art. 53 LR • The next phase of the greenfield project in Sisslerfeld (Eiken, Switzerland) will be implemented as part of a strategic collaboration. • Total investment amounts to more than CHF 500 million. • Start of commercial production at the new site is expected in 2030.

Brings extensive experience in patient care, dermatologic research and commercialization

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher’s prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist’s real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

With PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.

University of Calgary research demonstrates more than 200-fold improvement in antibacterial performance while Biosenta advances commercialization